38
Participants
Start Date
April 30, 2023
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2026
KM602
Multiple dose levels of KM602 will be administered, including 0.01 mg/kg QW, 0.1 mg/kg QW, 0.6 mg/kg QW, 3 mg/kg QW, and 10 mg/kg QW. KM602 is administered intravenously once a week, and each cycle is 21 days.
Beijing Cancer Hospital, Beijing
Xuanzhu Biopharmaceutical Co., Ltd.
INDUSTRY